We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

bioMérieux

Designs, develops, manufactures and markets in vitro diagnostics systems used in clinical and industrial applications read more Featured Products: More products

Download Mobile App




bioMérieux Acquires Software Company LUMED to Support Fight against Antimicrobial Resistance

By LabMedica International staff writers
Posted on 12 Jan 2024
Print article
Image: bioMérieux has acquired the entire share capital of LUMED for about EURO 9 million (Photo courtesy of LUMED)
Image: bioMérieux has acquired the entire share capital of LUMED for about EURO 9 million (Photo courtesy of LUMED)

bioMérieux (Marcy-l’Étoile, France), a world leader in the field of in vitro diagnostics, has acquired LUMED (Sherbrooke, Canada), an innovative software company, by purchasing its entire share capital for close to EURO 9 million.

The proper usage of available data is vital for hospitals to deliver safe and appropriate patient care, and control pharmacy costs. The vast amounts of diagnostic and other vital data generated along the healthcare pathway analyzed by intelligent software can play a key role in assisting health professionals in their decision-making process, thus achieving optimal benefits for patients. LUMED has developed a clinical decision support system that aids hospitals in optimizing their antimicrobial prescriptions and monitoring healthcare-associated infections. LUMED’s advanced software solutions ensure that local antimicrobial prescription guidelines are adhered to and duly implemented. It provides all the varied and relevant information that healthcare professionals need to optimize their Antimicrobial Stewardship Programs (ASP) and their Infection Prevention and Control (IPC) programs, offer better care for their patients, fight antimicrobial resistance (AMR), and improve infection control.

LUMED’s solutions perfectly complement bioMérieux’s comprehensive suite of software solutions - BIOMÉRIEUX VISION SUITE - which gathers and organizes laboratory and hospital data into insightful and actionable information to support diagnostic and clinical decisions at all stages, from individual patient care to public health surveillance, to combat AMR and support antimicrobial stewardship. By providing a comprehensive suite of software products and services that collect, analyze, and merge various sources of data, BIOMÉRIEUX VISION SUITE empowers users to make the right decisions at the right time. The LUMED acquisition is in line with bioMérieux’s efforts to expand its data analytics portfolio, with continued focus and commitment to antimicrobial stewardship and infection prevention and control. bioMérieux plans to leverage its global commercial network to bring LUMED software’s benefits to the largest possible number of patients.

“For bioMérieux, it is essential that we extend the scope of diagnostic testing beyond the laboratory itself,” said Jennifer Zinn, Executive Vice President, Clinical Operations, bioMérieux. “Today, many hospitals around the world are structuring themselves around the major issue of antimicrobial resistance and infection prevention. With LUMED, we provide solutions for antimicrobial stewardship teams to improve their daily workflow. The software contributes to optimizing the process of care delivery, as well as costs and patient management.”

"This acquisition marks a significant milestone in our journey,” added Vincent Nault, Chief Executive Officer, LUMED. “Joining forces with bioMérieux aligns with our commitment to advancing antimicrobial stewardship and infection prevention through our cutting-edge modules—such as APSS and ZINC. We believe that combining LUMED's innovative software solutions with bioMérieux's global reach and expertise in diagnostics will create a powerful synergy. Together, we can further enhance patient care, combat antimicrobial resistance, and contribute to the evolution of healthcare practices."

Related Links:
bioMérieux
LUMED

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: The new ADLM guidance will help healthcare professionals navigate respiratory virus testing in a post-COVID world (Photo courtesy of 123RF)

New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections

Respiratory tract infections, predominantly caused by viral pathogens, are a common reason for healthcare visits. Accurate and swift diagnosis of these infections is essential for optimal patient management.... Read more

Molecular Diagnostics

view channel
Image: The HelioLiver Dx test has met the coprimary and secondary study endpoints in the CLiMB trial (Photo courtesy of Helio Genomics)

Blood-Based Test Outperforms Ultrasound in Early Liver Cancer Detection

Patients with liver cirrhosis and chronic hepatitis B are at a higher risk for developing hepatocellular carcinoma (HCC), the most prevalent type of liver cancer. The American Association for the Study... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Microbiology

view channel
Image: The POC PCR test shortens time for STI test results (Photo courtesy of Visby Medical)

POC STI Test Shortens Time from ED Arrival to Test Results

In a 2024 sexually transmitted infections (STIs) surveillance report by the World Health Organization (WHO), over 2.5 million cases were recorded, alongside a rise in the inappropriate use of antibiotics... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.